Form 4: Spyre Therapeutics' Chief Medical Officer Granted 400,000 Stock Options
SEC Form 4 Filing
Chief Medical Officer of Spyre Therapeutics, Sheldon Sloan, was granted options to purchase 400,000 shares of common stock on October 1, 2024.
Summary
- Sheldon Sloan, the Chief Medical Officer of Spyre Therapeutics, Inc., was granted stock options on October 1, 2024.
- The options allow Sloan to purchase 400,000 shares of Spyre Therapeutics' common stock at an exercise price of $27.46 per share.
- The options vest over a four-year period, with 25% vesting on October 1, 2025, and the remaining 75% vesting in monthly installments over the subsequent three years, contingent upon continued employment.
- The options expire on October 1, 2034.
Sentiment
Score: 7
Explanation: The document is a routine disclosure of stock option grants, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value. The sentiment is slightly positive as it indicates investment in key personnel.
Positives
- The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant (400,000 shares) would need to be compared to grants given to CMOs at comparable companies (e.g., similar market cap, stage of development) to assess its relative magnitude.
- Vesting schedules of four years with a one-year cliff (25% vesting after one year) are typical.
Stakeholder Impact
- Shareholders: The grant aligns the Chief Medical Officer's interests with increasing shareholder value.
- Employees: The grant may have a positive impact on employee morale as it shows investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Date of the stock option grant and earliest transaction date. |
| 10/01/2025 | Date when the first 25% of the stock options vest. |
| 10/01/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.